L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Moleculin Biotech, Inc.
Related studies linked through entity extraction aliases.
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
- Status
- RECRUITING
- Phase
- PHASE2
Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)
- Status
- COMPLETED
- Phase
- PHASE1
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2